Cover: Re

Re

Surveys Identify Barriers to Participation in Clinical Trials

Published in: Journal of the National Cancer Institute, v. 93, no. 3, Feb. 7, 2001, p. 238-239

by Nikhil Wagle, Dana P. Goldman, Meredith L. Kilgore

Read More

Access further information on this document at www.ingentaconnect.com

This study was published in a peer-reviewed scholarly journal. The full text of the study can be found at the link above.

Abstract

One of the most pressing issues in clinical cancer research is the relatively small number of patients enrolled in clinical trials. In a recent two-part News series, R. Finn wrote, "fewer than 3% of adults with cancer participate in clinical trials." This figure is the most commonly used statistic in discussing cancer trial participation. However, this figure misrepresents the number of cancer patients treated in experimental therapeutic trials. The cancer community should recognize that the 3% rate refers to CTEP-sponsored studies only and not to all clinical cancer trials. Estimates of participation rates do not recognize the complicated interplay between patients, providers, insurers, and institutions that ultimately contributes to patient involvement in clinical trials.

Research conducted by

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.